Diasorin SpA

DIA: XMIL (ITA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
€294.00QmqldbJygwpzv

Narrow-Moat DiaSorin Has Another Strong Quarter, Completes Luminex Deal With Coronavirus Test Cash

Narrow-moat DiaSorin had a strong second quarter and largely met our high expectations with top-line growth of 35% and profit growth of 26%. We maintain our EUR 112 fair value estimate, with strong near-term results offset by our expectation for the U.S. corporate tax rate to rise to a probability-weighted 26%.

Sponsor Center